| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Homosexuality, Male | 189 | 2024 | 483 | 39.180 |
Why?
|
| Bisexuality | 122 | 2020 | 210 | 30.540 |
Why?
|
| Sexual Behavior | 116 | 2023 | 634 | 17.870 |
Why?
|
| HIV Infections | 165 | 2024 | 2535 | 16.260 |
Why?
|
| Sexual Partners | 85 | 2020 | 325 | 14.400 |
Why?
|
| Risk-Taking | 95 | 2020 | 456 | 12.240 |
Why?
|
| Unsafe Sex | 66 | 2018 | 162 | 11.980 |
Why?
|
| Substance-Related Disorders | 84 | 2021 | 825 | 10.520 |
Why?
|
| HIV Seropositivity | 56 | 2018 | 196 | 8.690 |
Why?
|
| Compulsive Behavior | 24 | 2023 | 31 | 6.780 |
Why?
|
| Condoms | 38 | 2020 | 148 | 6.260 |
Why?
|
| Adult | 226 | 2024 | 13458 | 5.790 |
Why?
|
| Male | 277 | 2024 | 22779 | 5.430 |
Why?
|
| New York City | 82 | 2019 | 283 | 5.230 |
Why?
|
| Young Adult | 126 | 2024 | 4936 | 4.940 |
Why?
|
| Internet | 26 | 2016 | 234 | 4.340 |
Why?
|
| Patient Acceptance of Health Care | 22 | 2019 | 471 | 4.150 |
Why?
|
| Humans | 292 | 2024 | 42163 | 4.060 |
Why?
|
| Middle Aged | 126 | 2019 | 11819 | 3.620 |
Why?
|
| Adolescent | 119 | 2024 | 5950 | 3.620 |
Why?
|
| Drug Users | 13 | 2019 | 51 | 3.470 |
Why?
|
| Anti-HIV Agents | 21 | 2021 | 475 | 3.340 |
Why?
|
| Risk Reduction Behavior | 18 | 2019 | 137 | 3.290 |
Why?
|
| Medication Adherence | 17 | 2021 | 177 | 3.210 |
Why?
|
| Safe Sex | 26 | 2019 | 78 | 3.090 |
Why?
|
| Alcohol Drinking | 20 | 2020 | 585 | 2.960 |
Why?
|
| Depression | 23 | 2019 | 837 | 2.850 |
Why?
|
| Motivation | 30 | 2019 | 492 | 2.820 |
Why?
|
| Mental Health | 16 | 2017 | 363 | 2.610 |
Why?
|
| Stress, Psychological | 12 | 2017 | 641 | 2.300 |
Why?
|
| Social Support | 15 | 2017 | 438 | 2.150 |
Why?
|
| HIV Seronegativity | 10 | 2019 | 41 | 2.110 |
Why?
|
| Counseling | 5 | 2019 | 134 | 2.090 |
Why?
|
| Patient Compliance | 14 | 2017 | 225 | 2.090 |
Why?
|
| Sexually Transmitted Diseases | 14 | 2018 | 172 | 2.080 |
Why?
|
| Amphetamine-Related Disorders | 7 | 2018 | 69 | 2.050 |
Why?
|
| Attitude to Health | 14 | 2015 | 336 | 2.040 |
Why?
|
| Methamphetamine | 10 | 2018 | 167 | 1.950 |
Why?
|
| Health Knowledge, Attitudes, Practice | 23 | 2019 | 959 | 1.880 |
Why?
|
| Central Nervous System Stimulants | 10 | 2018 | 181 | 1.860 |
Why?
|
| Self Disclosure | 9 | 2017 | 43 | 1.840 |
Why?
|
| Sexual Dysfunctions, Psychological | 4 | 2023 | 13 | 1.810 |
Why?
|
| Homosexuality | 8 | 2016 | 35 | 1.740 |
Why?
|
| Homosexuality, Female | 7 | 2012 | 60 | 1.720 |
Why?
|
| Interpersonal Relations | 16 | 2017 | 216 | 1.700 |
Why?
|
| Female | 97 | 2024 | 24018 | 1.660 |
Why?
|
| Self Concept | 6 | 2019 | 170 | 1.590 |
Why?
|
| Emotions | 7 | 2018 | 251 | 1.560 |
Why?
|
| Communication | 6 | 2019 | 207 | 1.540 |
Why?
|
| Anti-Retroviral Agents | 9 | 2021 | 158 | 1.520 |
Why?
|
| Stereotyping | 6 | 2013 | 45 | 1.510 |
Why?
|
| United States | 41 | 2024 | 5072 | 1.500 |
Why?
|
| Social Behavior | 10 | 2015 | 160 | 1.490 |
Why?
|
| Patient Selection | 7 | 2018 | 192 | 1.470 |
Why?
|
| Viral Load | 15 | 2021 | 344 | 1.450 |
Why?
|
| Urban Population | 14 | 2016 | 364 | 1.450 |
Why?
|
| Aged | 45 | 2020 | 7982 | 1.450 |
Why?
|
| Mass Screening | 9 | 2019 | 531 | 1.420 |
Why?
|
| Socioeconomic Factors | 20 | 2016 | 1221 | 1.380 |
Why?
|
| Health Behavior | 10 | 2020 | 568 | 1.320 |
Why?
|
| Self Efficacy | 15 | 2021 | 211 | 1.300 |
Why?
|
| Prevalence | 23 | 2021 | 1597 | 1.290 |
Why?
|
| Cross-Sectional Studies | 36 | 2018 | 3077 | 1.290 |
Why?
|
| Psychometrics | 8 | 2018 | 350 | 1.280 |
Why?
|
| Longitudinal Studies | 14 | 2019 | 1020 | 1.210 |
Why?
|
| Prescription Drugs | 3 | 2015 | 32 | 1.200 |
Why?
|
| Family Characteristics | 8 | 2019 | 124 | 1.190 |
Why?
|
| Child Abuse, Sexual | 4 | 2018 | 22 | 1.190 |
Why?
|
| Risk Factors | 31 | 2018 | 3942 | 1.180 |
Why?
|
| Minority Groups | 7 | 2017 | 663 | 1.160 |
Why?
|
| Health Surveys | 15 | 2018 | 401 | 1.150 |
Why?
|
| Decision Making | 4 | 2019 | 242 | 1.130 |
Why?
|
| Interviews as Topic | 15 | 2019 | 428 | 1.120 |
Why?
|
| Erotica | 2 | 2018 | 3 | 1.120 |
Why?
|
| Men | 4 | 2017 | 19 | 1.120 |
Why?
|
| Social Identification | 5 | 2014 | 63 | 1.080 |
Why?
|
| Alcoholism | 8 | 2014 | 292 | 1.070 |
Why?
|
| Data Collection | 14 | 2015 | 210 | 1.070 |
Why?
|
| Marijuana Smoking | 3 | 2019 | 90 | 1.070 |
Why?
|
| Personal Satisfaction | 7 | 2019 | 74 | 1.060 |
Why?
|
| Anxiety | 10 | 2019 | 847 | 1.050 |
Why?
|
| Behavior Therapy | 7 | 2010 | 179 | 1.030 |
Why?
|
| Gender Identity | 5 | 2017 | 117 | 1.000 |
Why?
|
| Spirituality | 2 | 2017 | 52 | 0.990 |
Why?
|
| Leisure Activities | 3 | 2011 | 38 | 0.980 |
Why?
|
| Object Attachment | 3 | 2019 | 27 | 0.980 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2019 | 200 | 0.960 |
Why?
|
| Cocaine-Related Disorders | 6 | 2014 | 99 | 0.930 |
Why?
|
| Alcohol-Related Disorders | 3 | 2012 | 63 | 0.910 |
Why?
|
| Executive Function | 2 | 2018 | 55 | 0.900 |
Why?
|
| Truth Disclosure | 6 | 2012 | 26 | 0.860 |
Why?
|
| Logistic Models | 15 | 2017 | 1001 | 0.850 |
Why?
|
| Models, Psychological | 6 | 2017 | 141 | 0.840 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2010 | 229 | 0.830 |
Why?
|
| Research Personnel | 3 | 2016 | 191 | 0.820 |
Why?
|
| Pilot Projects | 12 | 2019 | 733 | 0.790 |
Why?
|
| Disease Transmission, Infectious | 2 | 2015 | 30 | 0.790 |
Why?
|
| Affect | 3 | 2015 | 177 | 0.790 |
Why?
|
| Health Promotion | 7 | 2018 | 691 | 0.780 |
Why?
|
| Social Environment | 6 | 2014 | 218 | 0.770 |
Why?
|
| Intention | 3 | 2018 | 103 | 0.730 |
Why?
|
| Hypnotics and Sedatives | 4 | 2015 | 27 | 0.730 |
Why?
|
| Transsexualism | 3 | 2011 | 20 | 0.730 |
Why?
|
| Personality Inventory | 4 | 2015 | 82 | 0.730 |
Why?
|
| Telemedicine | 4 | 2019 | 215 | 0.710 |
Why?
|
| AIDS Serodiagnosis | 5 | 2017 | 25 | 0.700 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 638 | 0.700 |
Why?
|
| Psychology | 3 | 2019 | 39 | 0.700 |
Why?
|
| Health Education | 5 | 2012 | 358 | 0.690 |
Why?
|
| Primary Prevention | 3 | 2016 | 63 | 0.680 |
Why?
|
| Comorbidity | 8 | 2019 | 725 | 0.650 |
Why?
|
| Age Factors | 13 | 2019 | 1139 | 0.630 |
Why?
|
| Patient Preference | 2 | 2018 | 55 | 0.620 |
Why?
|
| Video Recording | 1 | 2019 | 40 | 0.620 |
Why?
|
| Home Care Services | 2 | 2017 | 37 | 0.620 |
Why?
|
| Factor Analysis, Statistical | 6 | 2014 | 157 | 0.610 |
Why?
|
| Serologic Tests | 1 | 2019 | 45 | 0.610 |
Why?
|
| Mental Disorders | 2 | 2015 | 377 | 0.610 |
Why?
|
| Depressive Disorder | 3 | 2017 | 185 | 0.610 |
Why?
|
| Military Personnel | 1 | 2020 | 109 | 0.600 |
Why?
|
| Program Evaluation | 5 | 2019 | 358 | 0.600 |
Why?
|
| Residence Characteristics | 3 | 2016 | 359 | 0.590 |
Why?
|
| Religion | 2 | 2017 | 90 | 0.590 |
Why?
|
| Qualitative Research | 8 | 2019 | 526 | 0.580 |
Why?
|
| Cognition | 3 | 2021 | 458 | 0.570 |
Why?
|
| HIV-1 | 3 | 2010 | 747 | 0.560 |
Why?
|
| Prospective Studies | 6 | 2018 | 1574 | 0.550 |
Why?
|
| Harm Reduction | 4 | 2007 | 27 | 0.550 |
Why?
|
| Human Development | 1 | 2017 | 9 | 0.550 |
Why?
|
| Population Density | 1 | 2017 | 32 | 0.540 |
Why?
|
| San Francisco | 14 | 2006 | 34 | 0.540 |
Why?
|
| Religion and Sex | 1 | 2017 | 2 | 0.530 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 1058 | 0.520 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 156 | 0.520 |
Why?
|
| Follow-Up Studies | 9 | 2015 | 1051 | 0.510 |
Why?
|
| Brazil | 4 | 2019 | 83 | 0.510 |
Why?
|
| Urethral Diseases | 1 | 2016 | 1 | 0.500 |
Why?
|
| Rectal Diseases | 1 | 2016 | 4 | 0.500 |
Why?
|
| Treatment Outcome | 12 | 2015 | 1586 | 0.490 |
Why?
|
| Sex Factors | 10 | 2016 | 1008 | 0.490 |
Why?
|
| Gonorrhea | 1 | 2016 | 24 | 0.480 |
Why?
|
| Crime Victims | 1 | 2016 | 77 | 0.480 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 15 | 0.460 |
Why?
|
| Men's Health | 2 | 2012 | 12 | 0.460 |
Why?
|
| Sex Education | 4 | 2014 | 36 | 0.460 |
Why?
|
| Perception | 6 | 2018 | 209 | 0.450 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2803 | 0.450 |
Why?
|
| Chlamydia Infections | 2 | 2018 | 199 | 0.450 |
Why?
|
| Self Care | 2 | 2013 | 173 | 0.440 |
Why?
|
| Disclosure | 2 | 2004 | 36 | 0.440 |
Why?
|
| Penis | 2 | 2012 | 90 | 0.430 |
Why?
|
| Voluntary Programs | 1 | 2014 | 4 | 0.430 |
Why?
|
| Culture | 5 | 2014 | 172 | 0.420 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2005 | 128 | 0.420 |
Why?
|
| Heterosexuality | 1 | 2014 | 96 | 0.400 |
Why?
|
| Group Processes | 1 | 2013 | 23 | 0.400 |
Why?
|
| New York | 7 | 2013 | 88 | 0.400 |
Why?
|
| Preventive Health Services | 1 | 2013 | 65 | 0.400 |
Why?
|
| Cohort Studies | 5 | 2018 | 1729 | 0.400 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 2018 | 225 | 0.400 |
Why?
|
| Antisocial Personality Disorder | 1 | 2013 | 20 | 0.400 |
Why?
|
| Patient Education as Topic | 5 | 2019 | 234 | 0.390 |
Why?
|
| Research Design | 6 | 2018 | 370 | 0.390 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 729 | 0.390 |
Why?
|
| Love | 1 | 2012 | 6 | 0.390 |
Why?
|
| Quality of Life | 1 | 2017 | 599 | 0.380 |
Why?
|
| Adult Survivors of Child Abuse | 3 | 2018 | 25 | 0.370 |
Why?
|
| Adaptation, Psychological | 3 | 2017 | 410 | 0.370 |
Why?
|
| Femininity | 1 | 2012 | 5 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 358 | 0.370 |
Why?
|
| Masculinity | 1 | 2012 | 19 | 0.370 |
Why?
|
| Hobbies | 1 | 2011 | 2 | 0.350 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 680 | 0.350 |
Why?
|
| Program Development | 4 | 2016 | 237 | 0.350 |
Why?
|
| Health Status Disparities | 2 | 2017 | 705 | 0.350 |
Why?
|
| Negotiating | 4 | 2016 | 26 | 0.350 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 573 | 0.350 |
Why?
|
| Science | 1 | 2011 | 23 | 0.340 |
Why?
|
| Risk Management | 1 | 2010 | 8 | 0.340 |
Why?
|
| Sampling Studies | 3 | 2016 | 64 | 0.340 |
Why?
|
| Time Factors | 6 | 2015 | 1848 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2018 | 280 | 0.340 |
Why?
|
| Models, Theoretical | 4 | 2017 | 230 | 0.330 |
Why?
|
| Religion and Psychology | 1 | 2010 | 27 | 0.330 |
Why?
|
| Sexuality | 2 | 2011 | 56 | 0.330 |
Why?
|
| Los Angeles | 6 | 2018 | 390 | 0.320 |
Why?
|
| Alcoholic Intoxication | 1 | 2010 | 21 | 0.320 |
Why?
|
| Regression Analysis | 6 | 2018 | 487 | 0.310 |
Why?
|
| Syphilis | 1 | 2009 | 24 | 0.310 |
Why?
|
| Psychotherapy, Group | 1 | 2009 | 23 | 0.310 |
Why?
|
| Interview, Psychological | 1 | 2009 | 63 | 0.310 |
Why?
|
| Focus Groups | 6 | 2016 | 398 | 0.310 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2009 | 54 | 0.310 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 26 | 0.300 |
Why?
|
| Smoking | 3 | 2012 | 1019 | 0.300 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 2019 | 7 | 0.300 |
Why?
|
| Analysis of Variance | 4 | 2014 | 574 | 0.300 |
Why?
|
| Feasibility Studies | 6 | 2019 | 238 | 0.290 |
Why?
|
| Family | 1 | 2009 | 192 | 0.290 |
Why?
|
| Clinical Competence | 1 | 2009 | 154 | 0.280 |
Why?
|
| Awareness | 2 | 2018 | 73 | 0.270 |
Why?
|
| Psychotherapy | 2 | 2023 | 56 | 0.270 |
Why?
|
| Risk Assessment | 8 | 2018 | 845 | 0.270 |
Why?
|
| Drug Prescriptions | 2 | 2007 | 60 | 0.270 |
Why?
|
| Sleep | 2 | 2019 | 179 | 0.260 |
Why?
|
| Thailand | 5 | 2014 | 51 | 0.260 |
Why?
|
| Spouse Abuse | 1 | 2007 | 51 | 0.250 |
Why?
|
| Life Change Events | 1 | 2007 | 107 | 0.250 |
Why?
|
| Needs Assessment | 1 | 2007 | 180 | 0.230 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2012 | 547 | 0.230 |
Why?
|
| Impulsive Behavior | 2 | 2016 | 54 | 0.230 |
Why?
|
| Loneliness | 2 | 2019 | 22 | 0.230 |
Why?
|
| Health Personnel | 2 | 2018 | 262 | 0.230 |
Why?
|
| Chi-Square Distribution | 4 | 2014 | 236 | 0.220 |
Why?
|
| Lysergic Acid Diethylamide | 3 | 2009 | 4 | 0.220 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2009 | 8 | 0.220 |
Why?
|
| Ketamine | 3 | 2009 | 12 | 0.220 |
Why?
|
| Body Image | 2 | 2017 | 87 | 0.220 |
Why?
|
| Prejudice | 3 | 2012 | 116 | 0.210 |
Why?
|
| Life Style | 1 | 2006 | 326 | 0.210 |
Why?
|
| Demography | 3 | 2009 | 195 | 0.200 |
Why?
|
| Terrorism | 1 | 2003 | 13 | 0.200 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 24 | 0.200 |
Why?
|
| Social Class | 2 | 2016 | 286 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2014 | 190 | 0.180 |
Why?
|
| Health Status | 5 | 2017 | 432 | 0.180 |
Why?
|
| Antiviral Agents | 2 | 2016 | 189 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2014 | 587 | 0.180 |
Why?
|
| Adolescent Behavior | 5 | 2016 | 270 | 0.170 |
Why?
|
| Child | 5 | 2023 | 3381 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 65 | 0.170 |
Why?
|
| Retrospective Studies | 2 | 2019 | 2485 | 0.170 |
Why?
|
| Injections | 2 | 2018 | 40 | 0.160 |
Why?
|
| HIV Long-Term Survivors | 2 | 2010 | 7 | 0.160 |
Why?
|
| Space-Time Clustering | 2 | 2009 | 3 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2019 | 22 | 0.150 |
Why?
|
| Social Perception | 3 | 2013 | 71 | 0.150 |
Why?
|
| Hallucinogens | 2 | 2009 | 29 | 0.150 |
Why?
|
| Sex Characteristics | 2 | 2012 | 253 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 24 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 51 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2014 | 245 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2018 | 44 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2019 | 141 | 0.140 |
Why?
|
| HIV | 1 | 2018 | 100 | 0.140 |
Why?
|
| Sodium Oxybate | 2 | 2009 | 3 | 0.140 |
Why?
|
| Shame | 1 | 2018 | 6 | 0.140 |
Why?
|
| Choice Behavior | 3 | 2007 | 91 | 0.140 |
Why?
|
| Defense Mechanisms | 1 | 2017 | 10 | 0.140 |
Why?
|
| Probability | 1 | 2018 | 82 | 0.140 |
Why?
|
| Fatigue | 1 | 2018 | 97 | 0.140 |
Why?
|
| Puberty | 1 | 2017 | 31 | 0.140 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 163 | 0.130 |
Why?
|
| Risk | 2 | 2016 | 289 | 0.130 |
Why?
|
| Minority Health | 1 | 2017 | 96 | 0.130 |
Why?
|
| Multilevel Analysis | 1 | 2015 | 21 | 0.120 |
Why?
|
| Conservation of Natural Resources | 1 | 2016 | 49 | 0.120 |
Why?
|
| Language | 2 | 2014 | 181 | 0.120 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 92 | 0.120 |
Why?
|
| Sex Offenses | 1 | 2015 | 43 | 0.110 |
Why?
|
| Cultural Characteristics | 2 | 2012 | 128 | 0.110 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 116 | 0.110 |
Why?
|
| Translating | 1 | 2014 | 18 | 0.110 |
Why?
|
| Analgesics | 1 | 2015 | 55 | 0.110 |
Why?
|
| Social Facilitation | 1 | 2014 | 6 | 0.110 |
Why?
|
| Personality Disorders | 1 | 2014 | 21 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 438 | 0.110 |
Why?
|
| Linear Models | 2 | 2013 | 311 | 0.110 |
Why?
|
| Domestic Violence | 1 | 2014 | 32 | 0.110 |
Why?
|
| Uncertainty | 2 | 2011 | 32 | 0.110 |
Why?
|
| Organ Size | 2 | 2012 | 167 | 0.110 |
Why?
|
| Social Responsibility | 2 | 2004 | 16 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 222 | 0.110 |
Why?
|
| Rural Population | 1 | 2017 | 352 | 0.110 |
Why?
|
| Personality | 1 | 2014 | 55 | 0.110 |
Why?
|
| Random Allocation | 1 | 2014 | 145 | 0.110 |
Why?
|
| Incidence | 2 | 2010 | 1054 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2013 | 206 | 0.100 |
Why?
|
| Utilization Review | 1 | 2013 | 17 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2013 | 24 | 0.100 |
Why?
|
| Psychotropic Drugs | 1 | 2013 | 17 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2013 | 102 | 0.100 |
Why?
|
| Urban Health | 1 | 2013 | 99 | 0.100 |
Why?
|
| Psychopathology | 1 | 2013 | 20 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2013 | 44 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 60 | 0.100 |
Why?
|
| Jealousy | 1 | 2012 | 2 | 0.100 |
Why?
|
| Marijuana Abuse | 1 | 2014 | 93 | 0.100 |
Why?
|
| Caffeine | 1 | 2012 | 28 | 0.100 |
Why?
|
| Cannabinoids | 1 | 2013 | 67 | 0.100 |
Why?
|
| Internal-External Control | 2 | 2009 | 60 | 0.090 |
Why?
|
| Educational Status | 1 | 2013 | 335 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 56 | 0.090 |
Why?
|
| Psychological Tests | 2 | 2013 | 56 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 708 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 281 | 0.090 |
Why?
|
| Observation | 1 | 2011 | 10 | 0.090 |
Why?
|
| Primary Health Care | 2 | 2017 | 362 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 287 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 206 | 0.090 |
Why?
|
| New Jersey | 1 | 2010 | 15 | 0.080 |
Why?
|
| Psychological Theory | 2 | 2009 | 25 | 0.080 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2009 | 1 | 0.080 |
Why?
|
| Birds | 1 | 2011 | 93 | 0.080 |
Why?
|
| Recreation | 1 | 2010 | 42 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 683 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 44 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2009 | 93 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 123 | 0.080 |
Why?
|
| Public Health | 1 | 2013 | 405 | 0.080 |
Why?
|
| Inservice Training | 1 | 2009 | 33 | 0.080 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 8 | 0.080 |
Why?
|
| Social Isolation | 2 | 2010 | 34 | 0.080 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2009 | 81 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 174 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2009 | 60 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 25 | 0.070 |
Why?
|
| Anecdotes as Topic | 2 | 2008 | 6 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2009 | 224 | 0.070 |
Why?
|
| Fear | 2 | 2015 | 271 | 0.070 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 208 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2012 | 1516 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 933 | 0.070 |
Why?
|
| Health Literacy | 1 | 2009 | 120 | 0.070 |
Why?
|
| Citalopram | 1 | 2006 | 3 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 249 | 0.070 |
Why?
|
| Goals | 1 | 2007 | 33 | 0.060 |
Why?
|
| Peer Group | 2 | 2005 | 173 | 0.060 |
Why?
|
| Cocaine | 1 | 2009 | 248 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 32 | 0.060 |
Why?
|
| Breast Self-Examination | 1 | 2006 | 13 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2006 | 18 | 0.060 |
Why?
|
| Ejaculation | 1 | 2005 | 11 | 0.060 |
Why?
|
| Women's Health | 1 | 2006 | 158 | 0.060 |
Why?
|
| Piperazines | 1 | 2005 | 117 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 362 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 711 | 0.050 |
Why?
|
| Self Administration | 1 | 2003 | 67 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2003 | 154 | 0.050 |
Why?
|
| Telephone | 1 | 2020 | 35 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 11 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 118 | 0.040 |
Why?
|
| Chlamydia | 1 | 2018 | 45 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 70 | 0.040 |
Why?
|
| Animals | 2 | 2013 | 16695 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 256 | 0.030 |
Why?
|
| Texas | 1 | 2018 | 428 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 27 | 0.030 |
Why?
|
| Social Conditions | 1 | 2015 | 13 | 0.030 |
Why?
|
| California | 2 | 2010 | 531 | 0.030 |
Why?
|
| Anthropology, Cultural | 1 | 2014 | 12 | 0.030 |
Why?
|
| Patient Participation | 2 | 2006 | 87 | 0.030 |
Why?
|
| Hierarchy, Social | 1 | 2014 | 9 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 50 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 8 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 18 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 98 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 129 | 0.030 |
Why?
|
| Computers | 1 | 2013 | 35 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 54 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 158 | 0.030 |
Why?
|
| Tennessee | 1 | 2013 | 88 | 0.030 |
Why?
|
| North Carolina | 1 | 2013 | 122 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 310 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 109 | 0.020 |
Why?
|
| Florida | 1 | 2013 | 461 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 233 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 211 | 0.020 |
Why?
|
| Michigan | 1 | 2010 | 52 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 250 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 661 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 162 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 45 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 1169 | 0.020 |
Why?
|
| Compulsive Personality Disorder | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 176 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2007 | 57 | 0.020 |
Why?
|
| Students | 1 | 2012 | 617 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2598 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2006 | 305 | 0.020 |
Why?
|
| Informed Consent | 1 | 2006 | 34 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 61 | 0.010 |
Why?
|
| Purines | 1 | 2005 | 40 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 35 | 0.010 |
Why?
|
| Sulfones | 1 | 2005 | 47 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 39 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 61 | 0.010 |
Why?
|
| Narration | 1 | 2005 | 37 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 151 | 0.010 |
Why?
|
| Testosterone | 1 | 2005 | 211 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 6490 | 0.010 |
Why?
|